Jovana Nikolić, MD

All articles by Jovana Nikolić, MD

Bone mineral density

Positive Results Seen With Trikafta Treatment in Cystic Fibrosis

A pilot study evaluating the benefits of Trikafta treatment for cystic fibrosis (CF) indicates a significant improvement in bone mineral density (BMD), body composition, and exercise capacity, according to a new article published in the journal Pediatric Pulmonology.  The study design included 9 CF patients treated with Trikafta and 9 control CF patients who never…

pulmonary fibrosis

New Data Support the Efficacy of TXR-1002 for IPF Treatment

Aria Pharmaceuticals revealed promising results from the third preclinical study of TRX-1002, an idiopathic pulmonary fibrosis (IPF) treatment candidate, that showed a significant decrease in absolute lung weight, fibrosis score, and collagen and hydroxyproline levels.   The findings, revealed in a press release, were presented at the 6th Annual Antifibrotic Drug Development Summit in Boston, Massachusetts. “People suffering from…

Intestinal microbiome

Microbiome Diversity in PAH Linked With Pulmonary Vascular Disease Severity

An imbalanced gut microbiome in people with pulmonary arterial hypertension (PAH) may generate increased concentrations of the proinflammatory microbial metabolite trimethylamine, along with lower levels of anti-inflammatory circulating short-chain fatty acids and secondary bile acids, according to a new study published in the American Journal of Respiratory and Critical Care Medicine. A team of researchers…

viral infection bacteria

PPI Treatment for CF May Carry Higher Risk of Respiratory Infections

Long-lasting proton pump inhibitor (PPI) treatment in people with cystic fibrosis (CF) appears to be linked with a twofold increase in the risk of Pseudomonas aeruginosa infection and no observable evidence of nutritional status improvement, according to a new study published in the journal Digestive and Liver Disease.  A retrospective matched cohort study was conducted on…

Next post in CF News Briefs